AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02397460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02200978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Given orally
Study NCT02200978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6MP
Description: Given orally
Study NCT02200978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6MP
Description: Given orally
Study NCT02200978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal injection
Description: Ara-C and dexamethasone
Study NCT02200978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intrathecal injection
Description: Ara-C and dexamethasone
Study NCT03328845 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Toujeo SoloStar
Description: Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
Study NCT04012307 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Candesartan Cilexetil 32mg
Description: Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.
Study NCT04012307 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atacand® PROTECT
Description: Atacand® PROTECT is manufactured by AstraZeneca GmbH, Germany. Each tablet contains 32 mg of candesartan cilexetil.
Study NCT04384770 — intervention group
Intervention type: RADIATION
Intervention: CT-guided Stereotactic Body Radiation Therapy
Description: Undergo CT-guided SBRT
Study NCT04384770 — intervention group
Intervention type: RADIATION
Intervention: MRI-guided Stereotactic Body Radiation Therapy
Description: Undergo MRI-guided SBRT
Study NCT04384770 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02547571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High volume PEG split-dose
Description: Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
Study NCT02547571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low volume PEG split-dose
Description: Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
Study NCT02547571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High volume PEG non split, day before
Description: Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
Study NCT02547571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low volume PEG non split, same day
Description: Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
Study NCT02547571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear liquid diet
Study NCT03328845 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tresiba
Description: Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
Study NCT03328845 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Humalog Kwikpen
Description: Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
Study NCT02984514 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron emission tomography with tracer 18F-deoxy glucose
Description: Assessment of activity of brown adipose tissue with positron emission tomography using the tracer 18F-deoxy glucose
Study NCT03870529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A Compound
Description: Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection
Study NCT03870529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Participants randomized to this arm will receive surgical resection
Study NCT02647255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Description: PE treatment>7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)
Study NCT02647255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone pulse
Description: methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
Study NCT02647255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse
Description: methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
Study NCT03466749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Eluting Balloon Catheter
Description: Paclitaxel Eluting Balloon Catheter
Study NCT00618709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: ATX-101 single dose
Study NCT00328094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous intravenous insulin infusion
Description: Tight glucose control versus standard of care
Study NCT00328094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous intravenous insulin infusion
Description: Tight glucose control versus standard of care
Study NCT00533052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective and Cognitive Skills Training
Description: 24-week, weekly, group behavioral weight loss treatment with affective and cognitive skills training
Study NCT04361214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Tolerability study of leflunomide 100 mg administered once daily for 3 days followed by 30 mg administered once daily for the duration of 2 - 7 days.
Study NCT02631902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Community-based exercise program with 3 weekly exercise sessions
Study NCT02631902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Community-based dietary intervention program
Study NCT02778841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly
Study NCT02710916 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SD-OCT Spectralis
Description: All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation
Study NCT02710916 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SD-OCT Spectralis
Description: All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation
Study NCT04047849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics, oral Azithromycin and oral Amoxicillin
Description: Azithromycin (500mg day one followed by 250mg per day for 4 more days) and amoxicillin (500mg orally three times daily for 7 days) for a total course of seven days of antibiotic therapy
Study NCT04233671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based relapse prevention and peer mentoring
Description: Importantly, the treatment will utilize a group format. Group process can serve as a vital agent in breaking down client denial about drug abuse problems. Groups have also been shown to be suitable for treating problems commonly associated with substance abuse, including depression, isolation, and shame.~Additionally, groups intrinsically have many rewarding benefits, including reducing isolation and enabling members to witness the recovery of others. The eight-week group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, then followed by group sessions led by peer mentors for an additional four weeks.
Study NCT04460534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diagnostic
Description: The principle of this study is to propose to patients in whom a COVID-19 infection is suspected and who are screened for the disease, the joint search for the virus in the semen.
Study NCT04819412 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ROTAVAC®
Description: ROTAVAC® with 5 minutes prior administration of 2.5 ml of buffer
Study NCT04819412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVAC 5C -F1
Description: ROTAVAC 5C formulation BBIL-R2014-1
Study NCT04819412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVAC 5C -F2
Description: ROTAVAC 5C formulation BBIL-R2014-2
Study NCT04484155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Micro Sclerostomy (MIMS)
Description: The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
Study NCT04422314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: T-Detect Lyme
Description: T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.
Study NCT05083052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propolis 15%
Description: oothpaste formulation with 15% propolis.
Study NCT05083052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propolis 10%
Description: Toothpaste formulation with 10% propolis.
Study NCT05083052 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation of toothpaste without active ingredient.
Study NCT04632056 — intervention group
Intervention type: DRUG
Intervention: Beovu
Description: There is no treatment allocation. Patients administered Beovu by prescription that have started before inclusion of the patient into the study were enrolled.
Study NCT04018807 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resource pamphlet
Description: The pamphlet will list violence prevention, mental health, and substance abuse services.
Study NCT04018807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Therapy
Description: Remote therapy sessions will include mindfulness exercises and motivational interviewing techniques.
Study NCT04746261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASSIP + treatment as usual
Description: ASSIP:~First session: Videotaped narrative interview focusing on the background to the suicidal crisis.~Second session: Video playback. The patient and the therapist watch the recorded interview together, stopping the film regularly to add information. The patient is given a psychoeducational text to read and comment on as homework.~Third session: Compilation of a written case formulation of the individual's vulnerability and triggering events that preceded the suicidal crisis. Individual preventive measures are developed by the patient and the therapist together and written down in a document that the patient keeps and which is attached to the patient's medical record.~Fourth session (optional): Mini-exposure.~Standardized letters: The therapist contacts the patient by letter during two years, every three months the first year and every six months the second year.~Treatment as usual: As described bellow
Study NCT04746261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual and patient safety
Description: All patients follow their usual care, regardless of whether they are treated with ASSIP or not. Usual care is multidisciplinary and combines psychotherapy, pharmacotherapy and other treatments, including referral to specialist psychiatric units or primary care. This depends on the assessments made by the patient's usual care provider. Treatment as usual is monitored by the research team through a standardised medical record review.~In order to increase patient safety, some standardisation of usual care takes place. The research nurse communicates with the referring healthcare provider to ensure that the patient receives a follow-up appointment within the usual care setting after the initial visit and the research team informs the usual care provider and acts when acute suicide risk is detected. In most sites, some information from SIS, CSSR-S and MINI assessments is noted in the patient's medical records.
Study NCT03328845 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NovoRapid
Description: Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
Study NCT04746261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual and patient safety
Description: All patients follow their usual care, regardless of whether they are treated with ASSIP or not. Usual care is multidisciplinary and combines psychotherapy, pharmacotherapy and other treatments, including referral to specialist psychiatric units or primary care. This depends on the assessments made by the patient's usual care provider. Treatment as usual is monitored by the research team through a standardised medical record review.~In order to increase patient safety, some standardisation of usual care takes place. The research nurse communicates with the referring healthcare provider to ensure that the patient receives a follow-up appointment within the usual care setting after the initial visit and the research team informs the usual care provider and acts when acute suicide risk is detected. In most sites, some information from SIS, CSSR-S and MINI assessments is noted in the patient's medical records.
Study NCT02093403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT02093403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor
Description: Given PO
Study NCT02093403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02093403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03945994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connecting People Intervention
Description: Improve the resourcefulness of social networks of people with mental health problems
Study NCT03734900 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: 5ml Placebo infusion of 0.9% Sodium Chloride
Study NCT03734900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: Device: Aeon Acti-PRP~5ml autologous platelet rich plasma injection
Study NCT03734900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PL injection
Description: Device: Aeon Acti-PRP~5ml autologous platelet lysate injection
Study NCT03871959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.
Study NCT03871959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEBIO1143
Description: 3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.
Study NCT03004924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP640
Description: Instill 1 drop of SHP640 (povidone-iodine \[PVPI\] 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
Study NCT03004924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PVP-I 0.6%
Description: Instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
Study NCT03004924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Instill 1 drop of placebo ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
Study NCT01325194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine
Description: 50 mg intrathecally three times
Study NCT02982044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suprasystolic (300 mmHg) cuff compressions
Description: 10 minutes of ECG-gated repeated suprasystolic (300 mmHg) cuff compressions, with inflation occurring every other heart cycle. These cuff compressions may be triggered 0 seconds, 0.2 seconds, or 0.4 seconds from the R spike (systole) on the ECG signal.
Study NCT02982044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip exercise
Description: 10 minutes of ECG-gated rhythmic handgrip exercise at 30% maximal voluntary contraction, with contraction occurring every other heart cycle
Study NCT02982044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive heat stress
Description: 10 minutes of passive heat stress at 42 degrees Celsius with a commercially available heating blanket
Study NCT01010399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks
Study NCT01010399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosamprenavir/ritonavir
Description: Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day
Study NCT02798120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 4%
Description: Open label, topical SB204 4%
Study NCT00463840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT00463840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Study NCT00463840 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study NCT00463840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT00463840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX 6
Description: this is an established regimen of Oxaliplatin+infusional 5FU/Leucovorin
Study NCT01048970 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional Assessment
Description: Patients will receive nutritional assessment one week prior to treatment until completing two courses of chemotherapy
Study NCT01048970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA-DHA arm
Description: Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
Study NCT00232466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Procedure:~The treatment consists of a transpedicular injection of polymethylmethacrylate bone cement into the collapsed vertebral body (maximal 2 vertebrae in 1 treatment session) using fluoroscopic guidance. The procedure is performed under the use of local anesthetics and the patient can be discharged the same day or after 1 night of hospital stay.
Study NCT06241066 — intervention group
Intervention type: OTHER
Intervention: no-Intervention
Description: no-Intervention
Study NCT00625404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
Study NCT00625404 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
Study NCT03317457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab and Tremelimumab
Description: immun checkpoint inhibitor
Study NCT03317457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Anthracycline
Study NCT04369235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tCES
Description: The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. tCES will be applied for 20 minutes at an intensity of 1.0 -1.5 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 6 weeks.
Study NCT04369235 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tCES
Description: The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham tCES will consist of a 5-second ramp up to 1.0-1.5 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.